<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112062</article-id><article-id pub-id-type="publisher-id">ACM-40269</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_60612166.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  扶正化瘀片与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较
  Comparison of the Therapeutic Effect of FuzhengHuayu Tablet and Polyene Phosphatidylcholine on Nonalcoholic Fatty Liver
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>莫</surname><given-names>伟斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>欧阳</surname><given-names>婉爱</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>广州市第八人民医院，广东 广州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>439</fpage><lpage>443</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨扶正化瘀片与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效。方法：本次研究中所纳入的研究对象为我院医治的120例非酒精性脂肪肝患者，选取的时间段为2019年1月至2019年12月，按不同的治疗方式分为对照组(n = 60)与观察组(n = 60)，对照组采用多烯磷脂酰胆碱治疗，观察组采用扶正化瘀片治疗。观察两组患者肝功能变化情况。结果：两组患者治疗前ALT、AST、TBil无明显差异(P &gt; 0.05)，治疗3周、治疗12周后观察组患者GGT指标均明显低于对照组患者(P &lt; 0.05)。两组治疗前后比较BMI值、W/H值，统计学差异明显(P &gt; 0.05)，但治疗后对照组实验组比较无统计学差异(P &lt; 0.05)。实验组、对照组治疗前B型超声积明显高于治疗后(P &gt; 0.05)；两组治疗后比较无明显差异(P &lt; 0.05)。结论：采用扶正化瘀片治疗非酒精性脂肪肝，能明显改善患者的肝功能指标及肝脏组织学评分，疗效确切，值得应用。
    Objective: To explore the therapeutic effect of FuzhengHuayu tablet and polyene phosphatidylcholine on nonalcoholic fatty liver. Methods: 120 cases of nonalcoholic fatty liver treated in our hospital were included in this study. The selected period was from January 2019 to December 2019. According to different treatment methods, they were divided into the control group (n = 60) and the observation group (n = 60). The control group was treated with polyene phosphatidylcholine, and the observation group was treated with FuzhengHuayu tablet. The changes of liver function in the two groups were observed. Results: There was no significant difference in alt, AST and TBIL between the two groups before treatment (P &gt; 0.05). GGT indexes of observation group were significantly lower than those of control group after 3 weeks and 12 weeks of treatment (P &lt; 0.05). The BMI and W/H of the two groups were compared before and after treatment, the difference was statistically significant (P &gt; 0.05), but there was no statistical difference between the two groups (P &lt; 0.05). The B-mode ultrasound volume of the experimental group and the control group before treatment was significantly higher than that after treatment (P &gt; 0.05); there was no significant difference between the two groups after treatment (P &lt; 0.05). Conclusion: Using FuzhengHuayu tablet to treat nonalcoholic fatty liver can obviously improve the liver function index and liver histology score of patients, the curative effect is accurate, and it is worth applying. 
  
 
</p></abstract><kwd-group><kwd>多烯磷脂酰胆，扶正化瘀片，非酒精性脂肪肝，疗效, Polyene Phosphatidyl Bile</kwd><kwd> FuzhengHuayu Tablet</kwd><kwd> Nonalcoholic Fatty Liver</kwd><kwd> Therapeutic Effect</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨扶正化瘀片与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效。方法：本次研究中所纳入的研究对象为我院医治的120例非酒精性脂肪肝患者，选取的时间段为2019年1月至2019年12月，按不同的治疗方式分为对照组(n = 60)与观察组(n = 60)，对照组采用多烯磷脂酰胆碱治疗，观察组采用扶正化瘀片治疗。观察两组患者肝功能变化情况。结果：两组患者治疗前ALT、AST、TBil无明显差异(P &gt; 0.05)，治疗3周、治疗12周后观察组患者GGT指标均明显低于对照组患者(P &lt; 0.05)。两组治疗前后比较BMI值、W/H值，统计学差异明显(P &gt; 0.05)，但治疗后对照组实验组比较无统计学差异(P &lt; 0.05)。实验组、对照组治疗前B型超声积明显高于治疗后(P &gt; 0.05)；两组治疗后比较无明显差异(P &lt; 0.05)。结论：采用扶正化瘀片治疗非酒精性脂肪肝，能明显改善患者的肝功能指标及肝脏组织学评分，疗效确切，值得应用。</p></sec><sec id="s2"><title>关键词</title><p>多烯磷脂酰胆，扶正化瘀片，非酒精性脂肪肝，疗效</p></sec><sec id="s3"><title>Comparison of the Therapeutic Effect of FuzhengHuayu Tablet and Polyene Phosphatidylcholine on Nonalcoholic Fatty Liver<sup> </sup></title><p>Weibin Mo, Wan’ai Ouyang</p><p>The Eighth People’s Hospital of Guangzhou, Guangzhou Guangdong</p><p>Received: Jan. 3<sup>rd</sup>, 2021; accepted: Jan. 25<sup>th</sup>, 2021; published: Feb. 5<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/1-1571894x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the therapeutic effect of FuzhengHuayu tablet and polyene phosphatidylcholine on nonalcoholic fatty liver. Methods: 120 cases of nonalcoholic fatty liver treated in our hospital were included in this study. The selected period was from January 2019 to December 2019. According to different treatment methods, they were divided into the control group (n = 60) and the observation group (n = 60). The control group was treated with polyene phosphatidylcholine, and the observation group was treated with FuzhengHuayu tablet. The changes of liver function in the two groups were observed. Results: There was no significant difference in alt, AST and TBIL between the two groups before treatment (P &gt; 0.05). GGT indexes of observation group were significantly lower than those of control group after 3 weeks and 12 weeks of treatment (P &lt; 0.05). The BMI and W/H of the two groups were compared before and after treatment, the difference was statistically significant (P &gt; 0.05), but there was no statistical difference between the two groups (P &lt; 0.05). The B-mode ultrasound volume of the experimental group and the control group before treatment was significantly higher than that after treatment (P &gt; 0.05); there was no significant difference between the two groups after treatment (P &lt; 0.05). Conclusion: Using FuzhengHuayu tablet to treat nonalcoholic fatty liver can obviously improve the liver function index and liver histology score of patients, the curative effect is accurate, and it is worth applying.</p><p>Keywords:Polyene Phosphatidyl Bile, FuzhengHuayu Tablet, Nonalcoholic Fatty Liver, Therapeutic Effect</p><disp-formula id="hanspub.40269-formula2"><graphic xlink:href="//html.hanspub.org/file/1-1571894x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-1571894x7_hanspub.png" /> <img src="//html.hanspub.org/file/1-1571894x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>非酒精性脂肪肝属于一种无过量饮酒史的临床病理综合征，其主要特征表现为肝实质细胞脂肪变性与脂肪贮积 [<xref ref-type="bibr" rid="hanspub.40269-ref1">1</xref>]。引起该疾病的独立危险因素诸多，例如肥胖、高血脂症等。近些年来，随着人们的生活方式及饮食结构均发生了变化，从而导致非酒精性脂肪肝的发病率逐渐呈上升趋势，若不及时采取有效、正确的治疗措施，可能会发展为肝硬化或是肝癌，对患者的生命安全与身体健康产生极大的影响 [<xref ref-type="bibr" rid="hanspub.40269-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40269-ref3">3</xref>]。因此，本文主要将2019年1月至2019年12月，我院医治的120例非酒精性脂肪肝患者为研究对象，分别采用多烯磷脂酰胆碱与扶正化瘀片治疗后，对其影响效果进行探讨。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>本次研究中所纳入的研究对象为我院医治的120例非酒精性脂肪肝患者，入组者均没有饮酒病史，排除了病毒性肝炎、药物性肝炎、自身免疫性肝炎、遗传相关性肝炎这些疾病所导致的转氨酶升高，影像学彩超出现了脂肪性肝病的改变，选取的时间段为2019年1月至2019年12月，按不同的治疗方式随机分为对照组(n = 60)与观察组(n = 60)，对照组采用多烯磷脂酰胆碱治疗，男48例，女12例，年龄24至63岁，平均(45.25 &#177; 4.34)岁。观察组采用扶正化瘀片治疗，男43例，女17例，年龄27至61岁，平均(44.72 &#177; 3.16)岁。两组患者比较各项资料，无统计学意义(P &gt; 0.05)，可以对比。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>两组患者均给予阿托伐他汀(生产厂家：辉瑞制药有限公司；批准文号：国药准字H20051407)治疗：初始剂量为10 mg/1次，1次/1日，剂量调整间隔时间最少为4周；最大使用剂量为80 mg/1日 [<xref ref-type="bibr" rid="hanspub.40269-ref4">4</xref>]。</p><p>对照组采用多烯磷脂酰胆碱(生产厂家：赛菲诺(北京)制药有限公司；批准文号：国药准字H200559010)治疗：初始剂量为2粒/1次，3次/1日，最大剂量不可超过6粒 [<xref ref-type="bibr" rid="hanspub.40269-ref5">5</xref>]。</p><p>观察组采用扶正化瘀片(生产厂家：上海黄海制药有限责任公司；批准文号：国药准字Z20050546)治疗：口服，4片/1次，3次/1日，24周为1个疗程 [<xref ref-type="bibr" rid="hanspub.40269-ref6">6</xref>]。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>(1) 肝功能评估：详细记录两组患者治疗前、治疗3周、治疗24周后的① 谷氨酸转氨酶(ALT)、② 天冬氨酸转氨酶(AST)、③ 总胆红素(TBil)、④ 谷氨酰转移酶(GGT)变化情况。</p><p>(2) 人体学指标评估：测量两组患者的体质量、身高、腰臀围，计算BMI与腰臀比(W/H)。BIM = 体质量(kg)/身高<sup>2</sup> (m<sup>2</sup>)，W/H = 腰围/臀围。</p><p>(3) B型超声检查评估：应用彩色多普勒超声仪检测两组肝脏影像 [<xref ref-type="bibr" rid="hanspub.40269-ref7">7</xref>]；积分判断标准为：① 近场回声增高、灶性高回声或肝光点增粗，各计1分；② 远肠回声衰减、肝肿大、肝内管道系统显示不清或无法辨认，各计2分。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用SPSS21.0分析，计量资料以( x &#175; &#177; s )表示，经t检验，差异有统计学意义为P &lt; 0.05。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组治疗前后功能变化比较</title><p>两组患者治疗前ALT、AST、TBil无明显差异(P &gt; 0.05)，治疗3周、治疗12周后观察组患者GGT指标均明显低于对照组患者(P &lt; 0.05)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of liver function between control group and observation group ( x &#175; &#177; s , n = 60</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >ALT (u/l)</th><th align="center" valign="middle" >AST (u/l)</th><th align="center" valign="middle" >TBil (umol/l)</th><th align="center" valign="middle" >GGT (U/l)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >治疗前</td><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >95.33 &#177; 38.57</td><td align="center" valign="middle" >72.96 &#177; 31.74</td><td align="center" valign="middle" >31.04 &#177; 7.94</td><td align="center" valign="middle" >41.45 &#177; 15.67</td></tr><tr><td align="center" valign="middle" >参照组</td><td align="center" valign="middle" >96.24 &#177; 31.26</td><td align="center" valign="middle" >74.21 &#177; 34.89</td><td align="center" valign="middle" >31.44 &#177; 5.70</td><td align="center" valign="middle" >42.53 &#177; 13.98</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >t</td><td align="center" valign="middle" >0.142</td><td align="center" valign="middle" >0.205</td><td align="center" valign="middle" >0.317</td><td align="center" valign="middle" >0.398</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.887</td><td align="center" valign="middle" >0.838</td><td align="center" valign="middle" >0.752</td><td align="center" valign="middle" >0.691</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >治疗3周</td><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >67.25 &#177; 18.14</td><td align="center" valign="middle" >57.54 &#177; 19.17</td><td align="center" valign="middle" >22.62 &#177; 3.73</td><td align="center" valign="middle" >39.25 &#177; 17.25</td></tr><tr><td align="center" valign="middle" >参照组</td><td align="center" valign="middle" >65.47 &#177; 17.86</td><td align="center" valign="middle" >53.28 &#177; 16.24</td><td align="center" valign="middle" >21.85 &#177; 2.94</td><td align="center" valign="middle" >33.31 &#177; 16.26</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >t</td><td align="center" valign="middle" >0.542</td><td align="center" valign="middle" >1.313</td><td align="center" valign="middle" >1.256</td><td align="center" valign="middle" >1.998</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.589</td><td align="center" valign="middle" >0.192</td><td align="center" valign="middle" >0.212</td><td align="center" valign="middle" >0.048</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >治疗24周</td><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >41.74 &#177; 13.76</td><td align="center" valign="middle" >41.92 &#177; 15.18</td><td align="center" valign="middle" >17.49 &#177; 5.09</td><td align="center" valign="middle" >36.72 &#177; 15.45</td></tr><tr><td align="center" valign="middle" >参照组</td><td align="center" valign="middle" >40.52 &#177; 14.08</td><td align="center" valign="middle" >39.45 &#177; 14.65</td><td align="center" valign="middle" >16.57 &#177; 5.28</td><td align="center" valign="middle" >30.28 &#177; 18.69</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >t</td><td align="center" valign="middle" >0.480</td><td align="center" valign="middle" >0.907</td><td align="center" valign="middle" >0.972</td><td align="center" valign="middle" >2.057</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.632</td><td align="center" valign="middle" >0.366</td><td align="center" valign="middle" >0.333</td><td align="center" valign="middle" >0.042</td></tr></tbody></table></table-wrap><p>表1. 对照组与观察组肝功能变化比较( x &#175; &#177; s , n = 60)</p></sec><sec id="s7_2"><title>3.2. 两组治疗前后BMI值、W/H值比较</title><p>两组治疗前后比较BMI值、W/H值，统计学差异明显(P &gt; 0.05)，但治疗后对照组实验组比较无统计学差异(P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of BMI and W/H between two groups before and after treatment ( x &#175; &#177; s , n = 60</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  rowspan="2"  >例数</th><th align="center" valign="middle"  colspan="2"  >治疗前</th><th align="center" valign="middle"  colspan="2"  >治疗后</th></tr></thead><tr><td align="center" valign="middle" >BMI值(kg/m<sup>2</sup>)</td><td align="center" valign="middle" >W/H值</td><td align="center" valign="middle" >BMI值(kg/m<sup>2</sup>)</td><td align="center" valign="middle" >W/H值</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >30.72 &#177; 4.12</td><td align="center" valign="middle" >0.96 &#177; 0.15</td><td align="center" valign="middle" >29.55 &#177; 3.78</td><td align="center" valign="middle" >0.94 &#177; 0.19</td></tr><tr><td align="center" valign="middle" >观察组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >31.22 &#177; 3.18</td><td align="center" valign="middle" >0.97 &#177; 0.23</td><td align="center" valign="middle" >29.86 &#177; 4.32</td><td align="center" valign="middle" >0.95 &#177; 0.11</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.744</td><td align="center" valign="middle" >0.282</td><td align="center" valign="middle" >0.418</td><td align="center" valign="middle" >0.353</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.458</td><td align="center" valign="middle" >0.778</td><td align="center" valign="middle" >0.677</td><td align="center" valign="middle" >0.725</td></tr></tbody></table></table-wrap><p>表2. 两组治疗前后BMI值、W/H值比较( x &#175; &#177; s , n = 60)</p></sec><sec id="s7_3"><title>3.3. 两组治疗前后B超积分变化比较</title><p>实验组治疗前后，B型超声积分别为(3.96 &#177; 2.13)分、(2.93 &#177; 1.02)分，治疗后明显低于治疗前(P &gt; 0.05) (t = 3.378, P = 0.001)；对照组分别为(3.86 &#177; 2.04)分、(2.87 &#177; 1.08)分，治疗后明显低于治疗前(P &gt; 0.05) (t = 3.322, P = 0.001)；两组治疗后比较无明显差异(t = 0.201, P = 0.841) (P &lt; 0.05)。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>以往临床上认为非酒精性脂肪肝预后效果良好，进展成肝纤维化、肝硬度的危险性非常小。有相关研究发现，肥胖患者发生肝硬化的几率高出普通人群6倍，部分严重肝脂肪变性可并发脂肪性肝炎、肝纤维化、肝硬化。此外，肝脏纤维化是肝脏功能出现病变后，才导致结缔组织呈纤维化变化，长时间脂肪肝易使肝脏功能衰弱，也存在肝脏细胞恶化的风险，引起纤维化。阿托伐他汀作为一种调脂良药，具有抑制胆固醇合成、降低胆固醇于脂蛋白水平，以及改善体内脂类代谢紊乱等作用，从而缓解患者的临床症状，降低纤溶酶的活性，进而预防肝纤维化；但是，若是单独使用该药物，患者易出现肌酸或是肌痛等不良反应。因此，需要与其他药物联合应用。多烯磷脂酰胆碱是从大豆中提取出来的一种高浓缩磷脂，其主要活性成分有2种，一种是多聚磷脂胆碱二酰甘油；另一种是乙酰卵磷脂，同时这2种物质也是组成所有细胞膜、亚细胞膜的主要部分 [<xref ref-type="bibr" rid="hanspub.40269-ref8">8</xref>]。当患者应用该药物后，可通过淋巴或血液循环途径，优先到达人体的肝脏并聚集，然后渗入到肝脏与亚细胞膜中，在肝细胞膜、细胞器膜以分子的形式进行特异性结合，最终和生物膜形成一部分，俱疲减少氧化应激，保护肝细胞的作用 [<xref ref-type="bibr" rid="hanspub.40269-ref9">9</xref>]。</p><p>扶正化瘀片作为一种中成药物，主要原料由丹参、五味子、冬虫夏草菌粉、桃仁、松花粉等诸多药物组成，具有以下4种功效：(1) 活血化瘀，可用来治疗肝淤血症；(2) 养肝精益，可用来治疗肝肾不足，适合肝肾虚弱者服用；(3) 可治疗乙型肝炎肝纤维化；(4) 可缓解由肝脏疾病所引起的头晕目涩等症状 [<xref ref-type="bibr" rid="hanspub.40269-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40269-ref11">11</xref>]。有相关研究报道，扶正化瘀片首个选取西药治疗失败，且难治性患者进行国药临床研究的中药，有望成为首个获准进入美国主流医药市场的复方中药 [<xref ref-type="bibr" rid="hanspub.40269-ref12">12</xref>]。经现代研究证实，扶正化瘀片可以有效的改善慢性乙型肝炎纤维化，使肝纤维化逆转率达到52%左右，对改善功能的总有效率高达74.1% [<xref ref-type="bibr" rid="hanspub.40269-ref13">13</xref>]。将该药物用于慢性乙型肝炎纤维化阻络瘀血、肝肾不足见上症的患者，能够通过抗脂过氧化，保护患者的肝细胞，对星状细胞的增殖、胶原合成进行抑制等，从而发挥出治疗肝纤维化的作用，具有① 减轻脂质过氧化损伤、② 调节免疫功能、③ 减轻肝脏炎症等诸多功效 [<xref ref-type="bibr" rid="hanspub.40269-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40269-ref15">15</xref>]。此外，肝脏中的GGT主要局限在毛细胆管与肝细胞微粒中，对鉴别黄疸有一定的意义，可反映出肝脏内的排泄障碍、肝外梗阻及肝硬化诊断、酒精肝损害过程。从以上研究中可看出，观察组采用扶正化瘀片治疗后，其肝功能指标均明显低于对照组(P &lt; 0.05)。</p><p>综上所述，扶正化瘀片具有活血化瘀、益精养肝的功效，用来治疗非酒精性脂肪肝患者，能延缓其肝纤维化进程，改善肝功能指标，疗效确切，值得应用。</p></sec><sec id="s9"><title>同意书</title><p>该文病例报道获得病人的知情同意。</p></sec><sec id="s10"><title>文章引用</title><p>莫伟斌,欧阳婉爱. 扶正化瘀片与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较Comparison of the Therapeutic Effect of FuzhengHuayu Tablet and Polyene Phosphatidylcholine on Nonalcoholic Fatty Liver[J]. 临床医学进展, 2021, 11(02): 439-443. https://doi.org/10.12677/ACM.2021.112062</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40269-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">肖敏. 多烯磷脂酰胆碱联合水飞蓟宾治疗非酒精性脂肪肝患者的临床效果分析[J]. 医学理论与实践, 2018, 31(6): 833-834.</mixed-citation></ref><ref id="hanspub.40269-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">郭振营. 胆宁片联合多烯磷脂酰胆碱治疗非酒精性脂肪肝疗效观察[J]. 实用中西医结合临床, 2018, 18(4): 72-74.</mixed-citation></ref><ref id="hanspub.40269-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">史文龙. 多烯磷脂酰胆碱联合二甲双胍对非酒精性脂肪肝患者血清IL-17及TGF-β水平的影响观察[J]. 现代诊断与治疗, 2018, 29(21): 3427-3428.</mixed-citation></ref><ref id="hanspub.40269-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Liu, R., He, J., Liu, X.F., et al. (2018) Microarray Analysis of Polyene Phosphatidylcholine Intervention on Rat Nonalcoholic Fatty Liver Cell Model. China Tissue Engineering Research, 22, 99-105.</mixed-citation></ref><ref id="hanspub.40269-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">安慎富, 杨娅娟, 燕飞. 中西医结合治疗非酒精性脂肪肝疗效观察[J]. 山西中医, 2019, 35(1): 25-26.</mixed-citation></ref><ref id="hanspub.40269-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">李滨, 张佳圆, 王凤永, 等. 胆宁片治疗非酒精性脂肪肝临床效果及对血脂、肝功能和肝纤维化的影响[J]. 解放军医药杂志, 2018, 30(10): 93-96.</mixed-citation></ref><ref id="hanspub.40269-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">朱桂丽. 多烯磷脂酰胆碱胶囊联合非诺贝特片治疗32例老年中重度非酒精性脂肪肝的临床研究[J]. 北方药学, 2019, 16(5): 95-96.</mixed-citation></ref><ref id="hanspub.40269-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">卢火明. 异甘草酸镁与多烯磷脂酰胆碱治疗脂肪肝对ALT、AST指标变化以及临床疗效的影响[J]. 中国实用医药, 2019, 14(3): 12-14.</mixed-citation></ref><ref id="hanspub.40269-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gao, J.L. (2019) Effect of Huazhuoquyu Formula Combined with Polyene Phosphatidylcholine on Liver Function and Blood Lipid Level in Patients with Nonalcoholic Fatty Liver. Chinese Folk Therapy, 27, 68-70.</mixed-citation></ref><ref id="hanspub.40269-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">李晓永, 张国顺. 扶正化瘀胶囊联合异甘草酸镁治疗失代偿期肝硬化患者的临床效果[J]. 中国医药导报, 2019, 16(11): 144-147.</mixed-citation></ref><ref id="hanspub.40269-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lu, J. (2019) Effect of Polyene Phosphatidylcholine Capsule Combined with Reduced Glutathione in the Treatment of Nonalcoholic Fatty Liver. Chinese Medical Journal of Minkang, 31, 28-30.</mixed-citation></ref><ref id="hanspub.40269-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">李玉贤, 张汾燕, 崔振. 熊去氧胆酸联合扶正化瘀胶囊治疗HBeAg阳性高病毒载量乙肝肝硬化患者的疗效及对肝纤维化和炎性因子的影响[J]. 现代中西医结合杂志, 2018, 27(18): 2016-2019.</mixed-citation></ref><ref id="hanspub.40269-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">霍苗苗, 程变巧, 林伟国. 扶正化瘀方对非酒精性脂肪性肝病大鼠肝纤维化及ACE-AngII-AT1R轴的影响[J]. 解放军医学杂志, 2018, 43(2): 114-119.</mixed-citation></ref><ref id="hanspub.40269-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Wu, J., Huang, X.T. and Peng, Y.Z. (2019) Clinical Observation of JieyuShugan Decoction Combined with Polyene Phosphatidylcholine Capsule in the Treatment of Nonalcoholic Fatty Liver. Journal of Practical Chinese Medicine, 35, 826-827.</mixed-citation></ref><ref id="hanspub.40269-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Li, J.J. (2019) Clinical Study on the Treatment of 44 Elderly Patients with Moderate and Severe Nonalcoholic Fatty Liver by Polyene Phosphatidylcholine Combined with Fenofibrate Tablets. Modern Medical Imaging, 28, 220-221.</mixed-citation></ref></ref-list></back></article>